Immune modulatory effects of oncogenic KRAS in cancer

Shaima’a Hamarsheh(University of Freiburg), Robert Zeiser(University of Freiburg)

Nature Communications

October 28, 2020

10.1038/s41467-020-19288-6

Cited by 373

Related Papers

Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells

|Blood|2007|393

The Nlrp3 inflammasome regulates acute graft-versus-host disease

|The Journal of Experimental Medicine|2013|233

Biglycan expression in the melanoma microenvironment promotes invasiveness via increased tissue stiffness inducing integrin-β1 expression

|Oncotarget|2017|65

Oncogenic <i>KrasG12D</i> Activation in the Nonhematopoietic Bone Marrow Microenvironment Causes Myelodysplastic Syndrome in Mice

|Molecular Cancer Research|2021|12